• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Pliant Therapeutics Inc.

    8/6/25 2:12:16 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    PLIANT THERAPEUTICS, INC

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    729139105

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    729139105


    1Names of Reporting Persons

    Morgan Stanley
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,737,335.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,737,335.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,737,335.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.1 %
    12Type of Reporting Person (See Instructions)

    HC, CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PLIANT THERAPEUTICS, INC
    (b)Address of issuer's principal executive offices:

    331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
    Item 2. 
    (a)Name of person filing:

    Morgan Stanley
    (b)Address or principal business office or, if none, residence:

    1585 Broadway, New York, NY 10036
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    729139105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    6.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Morgan Stanley
     
    Signature:Chris O'Hara
    Name/Title:Authorized Signatory, Morgan Stanley
    Date:08/06/2025
    Get the next $PLRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLRX

    DatePrice TargetRatingAnalyst
    3/4/2025Buy → Hold
    Needham
    3/4/2025Neutral
    Cantor Fitzgerald
    3/3/2025Buy → Hold
    Stifel
    3/3/2025Outperform → Market Perform
    Leerink Partners
    2/10/2025Overweight → Neutral
    Analyst
    2/10/2025$43.00 → $4.00Buy → Hold
    Canaccord Genuity
    2/10/2025Outperform → Perform
    Oppenheimer
    2/10/2025$40.00 → $4.00Buy → Neutral
    Citigroup
    More analyst ratings

    $PLRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in integrin-based drug development, today provided a corporate update and reported second quarter 2025 financial results. "While our activities in the quarter focused on the closure of BEACON-IPF and workforce realignment, we also took actions to ensure that we maintain core capabilities in support of Pliant's next steps," said Bernard Cou

    8/7/25 4:05:00 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Provides Update on BEACON-IPF

    Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). BEACON-IPF Trial Update BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary disco

    6/27/25 4:05:00 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

    SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025. Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS from Multiple ILD SubtypesIn a featured oral presentation, Johanna Schaub, Ph.D., Director of Translational Sciences at Pliant Therapeutics, discussed an evaluation of the antifibrotic activity of bexotegrast in fibrotic human precision-cut lung slices (PCLS) generated from non-id

    5/21/25 4:03:00 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    SEC Filings

    View All

    SEC Form 10-Q filed by Pliant Therapeutics Inc.

    10-Q - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

    8/7/25 4:22:31 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

    8/7/25 4:16:38 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Pliant Therapeutics Inc.

    SCHEDULE 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

    8/6/25 2:12:16 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pliant Therapeutics downgraded by Needham

    Needham downgraded Pliant Therapeutics from Buy to Hold

    3/4/25 8:19:24 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Pliant Therapeutics

    Cantor Fitzgerald resumed coverage of Pliant Therapeutics with a rating of Neutral

    3/4/25 7:42:23 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics downgraded by Stifel

    Stifel downgraded Pliant Therapeutics from Buy to Hold

    3/3/25 3:36:54 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Bruhn Suzanne Louise

    4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

    6/9/25 8:44:53 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Knobil Katharine

    4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

    6/9/25 8:44:41 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mccourt Thomas A

    4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

    6/9/25 8:44:23 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    Financials

    Live finance-specific insights

    View All

    Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

    SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take

    3/13/25 7:20:00 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

    Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced

    2/4/24 3:29:07 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

    Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12 Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data f

    9/26/23 7:30:00 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pliant Therapeutics Inc.

    SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

    11/14/24 9:00:58 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

    SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

    11/14/24 5:05:23 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

    SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

    11/14/24 4:47:50 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    Leadership Updates

    Live Leadership Updates

    View All

    Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

    Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discontinued following recommendation from expanded data safety monitoring board (DSMB). Following a prespecified data review and recommendation by the trial's independent DSMB, as well as a secondary r

    3/3/25 4:05:00 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer

    Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of product development, process optimization and manufacturing experience across multiple drug modalities, including small molecules. In this role, Dr. Imbert will lead chemistry, manufacturing and control (CMC)-related acti

    1/22/25 8:00:00 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

    BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. "A highlight to this quarter's progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is enrolling well and on track to complete enrollment in the first quarter of 2025," said Bernard Coulie, M.D., Ph.D.

    11/7/24 4:05:00 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care